topotecan pliva 4 milligram pdr/conc/soln for infus
pliva pharma limited - topotecan hydrochloride - pdr/conc/soln for infus - 4 milligram
topotecan 1mg1ml concentrate for solution for infusion vials
medac uk - topotecan hydrochloride - solution for infusion - 1mg/1ml
topotecan 4mg4ml concentrate for solution for infusion vials
medac uk - topotecan hydrochloride - solution for infusion - 1mg/1ml
topotecan martindale pharma 4 milligram pdr/conc/soln for infus
martindale pharmaceuticals ltd - topotecan hydrochloride - pdr/conc/soln for infus - 4 milligram
topotecan martindale pharma 1 milligram pdr/conc/soln for infus
martindale pharmaceuticals ltd - topotecan hydrochloride - pdr/conc/soln for infus - 1 milligram
hycamtin powder for solution
novartis pharmaceuticals canada inc - topotecan (topotecan hydrochloride) - powder for solution - 4mg - topotecan (topotecan hydrochloride) 4mg - antineoplastic agents
topotecan ebewe 1 mg/ml concentrate for soln for inf
ebewe pharma ges.m.b.h nfg. kg - topotecan hydrochloride - concentrate for soln for inf - 1 mg/ml
hycamtin 0.25 mg
novartis israel ltd - topotecan as hydrochloride - hard gelatin capsules - topotecan as hydrochloride 0.25 mg - topotecan - topotecan - indicated for the treatment of patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.
hycamtin 1 mg
novartis israel ltd - topotecan as hydrochloride - hard gelatin capsules - topotecan as hydrochloride 1 mg - topotecan - topotecan - indicated for the treatment of patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.
hycamtin topotecan (as hydrochloride) 4mg powder for injection vial
sandoz pty ltd - topotecan hydrochloride, quantity: 4 mg - injection, powder for - excipient ingredients: sodium hydroxide; tartaric acid; hydrochloric acid; mannitol - for single agent therapy for the treatment of patients with: small cell lung carcinoma, after failure of first line chemotherapy. metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. in combination with cisplatin for the treatment of patients with: histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy.